HCT/P

MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year

MARIETTA, Ga., Feb. 3, 2017 /PRNewswire/ — MiMedx Group, Inc. MDXG 2.31%, the leading regenerative medicine company utilizing human amniotic…